Clinical Trial

A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a FiH phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of \[177Lu\]Lu-ABY-271 in subjects with HER2 positive metastatic breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-15.
Trial Details
NCT Number NCT07081555
Lead Sponsor Affibody
Conditions Metastatic Breast Cancer, HER2 + Breast Cancer
Enrollment 21 participants
Start Date 2025-10-06
Primary Completion 2027-01-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-01